Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195325 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00195325 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 45 participants.
The verdict
NCT00195325, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
Interventions
- DRUG TTI-237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195325
The ClinicalTrials.gov registry entry for NCT00195325 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TTI-237 is the first listed.
NCT00195325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195325 about?
NCT00195325 is a clinical study titled "Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.". The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
What is the current status of trial NCT00195325?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00195325?
The interventions under investigation include: TTI-237 (DRUG).
Who is sponsoring clinical trial NCT00195325?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.